Key Points
- Tarsus Pharmaceuticals CEO Bobak Azamian sold 10,000 shares on June 17 at an average price of $61.55, totaling $615,500. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- The company recently reported better-than-expected quarterly results, posting EPS of -$0.16 versus the -$0.40 consensus estimate and revenue of $162.05 million, above estimates of $149.60 million.
- Analysts remain generally positive on TARS, with a consensus rating of “Moderate Buy” and an average price target of $90.67, while institutional investors continue to hold a large majority of the stock.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total value of $615,500.00. Following the completion of the transaction, the chief executive officer owned 847,991 shares in the company, valued at $52,193,846.05. This represents a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tarsus Pharmaceuticals Price Performance
TARS stock opened at $63.56 on Tuesday. The business has a fifty day moving average of $63.00 and a two-hundred day moving average of $69.20. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of -55.75 and a beta of 0.49. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.24. The company had revenue of $162.05 million for the quarter, compared to the consensus estimate of $149.60 million. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%. As a group, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -0.59 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms have commented on TARS. Oppenheimer began coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They issued an "outperform" rating and a $98.00 target price on the stock. Guggenheim boosted their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a "buy" rating in a research note on Wednesday, February 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, April 21st. HC Wainwright reaffirmed a "buy" rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Finally, Zacks Research cut shares of Tarsus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $90.67.
View Our Latest Report on TARS
Institutional Investors Weigh In On Tarsus Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of TARS. RTW Investments LP lifted its stake in Tarsus Pharmaceuticals by 5.0% during the 4th quarter. RTW Investments LP now owns 3,335,320 shares of the company's stock worth $273,096,000 after acquiring an additional 157,884 shares in the last quarter. Deep Track Capital LP boosted its holdings in Tarsus Pharmaceuticals by 71.4% during the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company's stock valued at $178,290,000 after acquiring an additional 1,250,000 shares during the period. Vanguard Group Inc. grew its position in Tarsus Pharmaceuticals by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company's stock valued at $196,476,000 after acquiring an additional 127,470 shares in the last quarter. Janus Henderson Group PLC grew its position in Tarsus Pharmaceuticals by 16.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company's stock valued at $157,223,000 after acquiring an additional 310,638 shares in the last quarter. Finally, Morgan Stanley increased its stake in Tarsus Pharmaceuticals by 6.7% during the fourth quarter. Morgan Stanley now owns 2,040,742 shares of the company's stock worth $167,096,000 after purchasing an additional 128,340 shares during the period. Hedge funds and other institutional investors own 90.01% of the company's stock.
Tarsus Pharmaceuticals Company Profile
(
Get Free Report)
Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.
In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
